♑ Capricorn Monthly Horoscope (1st July 2026 to 31st July 2026): The Capricorn Monthly Horoscope indicates a month focused on work and pers...

Indian reinsurer GIC Re is strategically shifting its overseas business focus. Amidst escalating climate-related losses globally, the compa...

Investor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...

Health officials revealed that in May 2026, 46 drug samples tested by Central Drugs Laboratories and 113 by State Drugs Testing Laboratorie...

Indian stock markets saw a positive start on Monday, with Sensex and Nifty inching up after Friday's dip. Tech Mahindra led the gains, whil...

Reliance Industries is poised for a turnaround, with strong earnings, a Jio Platforms IPO, and AI/energy investments promising significant ...

Private equity giant Carlyle is gearing up for significant IPOs in India, planning a $500 million listing for its automotive platform, High...

Indian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...

A sector leader is not just the company with the largest market share. Market share matters, but it is a result, not a cause. The cause is ...

India's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...

Reliance Industries is set to reinvent its oil-to-chemicals business. The company will convert crude oil into advanced materials and green ...

This collaboration leverages Novyte's AI engine for materials discovery and Chemvera's manufacturing expertise, creating an end-to-end Indi...

Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...

Easing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...